Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy (LEVO-CTEPH)

The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy: a Single-center Pilot Prospective Randomized Placebo-controlled Double-blind Clinical Trial

A single-center pilot prospective randomized placebo-controlled double-blind clinical trial.

Study objective - to investigate the efficacy and safety of levosimendan in patients in the perioperative period following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH).

Research Objectives:

  1. To assess the impact of levosimendan administration on pulmonary artery pressure during the perioperative period in patients who have undergone pulmonary endarterectomy for CTEPH.
  2. To evaluate the effect of levosimendan administration on right ventricular function parameters during the perioperative period in patients after pulmonary endarterectomy for CTEPH.
  3. To determine the influence of levosimendan on the need for inotropic and vasopressor support (VIS) during the perioperative period in patients following pulmonary endarterectomy for CTEPH.
  4. To examine the effect of levosimendan on the clinical course and complications during the postoperative period in patients after pulmonary endarterectomy for CTEPH.
  5. To evaluate the cardioprotective effect of levosimendan in patients following pulmonary endarterectomy for CTEPH.
  6. To assess the impact of levosimendan on in-hospital mortality in patients after pulmonary endarterectomy for CTEPH.

Studieoversikt

Detaljert beskrivelse

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and severe form of pulmonary hypertension resulting from thrombotic obstruction of the pulmonary arteries. It is typically a late complication of acute pulmonary embolism. The incidence of CTEPH has been reported to reach 13 cases per million population per year.

Organized thrombotic masses cause stenosis or obstruction of the pulmonary arteries, leading to increased pulmonary artery pressure and pulmonary vascular resistance. This results in redistribution of pulmonary blood flow, microangiopathy, and remodeling of small-caliber pulmonary vessels. Pulmonary endarterectomy (PEA) is the recommended standard of care for patients with CTEPH and can be curative. In experienced centers, mortality rates are less than 5%.

Residual pulmonary hypertension after PEA, defined as a mean pulmonary artery pressure ≥25 mmHg, occurs in 17-51% of patients. This complication is associated with residual thrombotic material in distal pulmonary arteries and small-vessel disease. Severe pulmonary hypertension causes right ventricular maladaptive remodeling and dysfunction, ultimately leading to right ventricular failure, which is the most important determinant of survival and quality of life. Residual pulmonary hypertension negatively affects long-term survival, with higher mortality associated with mean pulmonary artery pressure ≥36 mmHg and pulmonary vascular resistance ≥416 dyn·s·cm-⁵.

Currently, a multimodal approach to CTEPH is being considered. Surgery addresses the primary component by removing thrombotic masses, but pharmacotherapy is required for the microvascular component and persistently elevated pulmonary artery pressure. Targeted therapies are costly, and their benefit remains unclear. Clinical guidelines currently recommend only symptomatic therapy for patients with residual pulmonary hypertension and right ventricular failure after PEA, and no optimal treatment strategy has been defined for this complication in the early postoperative period.

Rationale for Levosimendan: Levosimendan has shown promising effects in pulmonary hypertension and right ventricular failure. Its mechanism of action involves opening ATP-dependent potassium channels in vascular smooth muscle cells, leading to vasodilation and reduction of both preload and afterload. Additionally, levosimendan binds to cardiac troponin C, increasing myofibril contractility. Previous studies have demonstrated that levosimendan reduces pulmonary artery pressure and pulmonary vascular resistance, improves right ventricular function (including increased TAPSE, ejection fraction, and cardiac output), and suppresses smooth muscle cell proliferation in pulmonary arteries. However, no studies to date have investigated the effect of levosimendan in patients with CTEPH undergoing pulmonary endarterectomy, and the drug has not previously been used in the perioperative management of this patient population.

Study objective is to evaluate the effect of levosimendan on pulmonary artery pressure and right ventricular function in patients undergoing pulmonary endarterectomy for CTEPH.

Studietype

Intervensjonell

Registrering (Antatt)

50

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Novosibirsk, Russland, 630055
        • Rekruttering
        • Meshalkin Research Institute of Pathology of Circulation

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Voluntary signed informed consent to participate in the study
  • Scheduled for pulmonary thromboendarterectomy surgery
  • Aged ≥18 years

Exclusion Criteria :

  • Patient refusal
  • Language barrier preventing understanding of the study
  • Severe renal failture (creatinine clearance <30 mL/min)
  • Severe hepatic insufficiency (Child-Pugh score >9 points)
  • Participation in other clinical trials
  • History of allergic reaction to levosimendan, Soluvit, or any of their components
  • Use of levosimendan within 30 days prior to screening

Discontinuation Criteria (or Withdrawal Criteria):

  • Need for extracorporeal membrane oxygenation (ECMO) support during the perioperative period
  • Pulmonary hemorrhage during the perioperative period

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Levosimendan

A levosimendan infusion after induction of anesthesia.

Infusion of levosimendan will be initiated after the induction of anesthesia, discontinued at the onset of patient cooling, and resumed at the time of rewarming at 34°C. The drug will be administered using an infusion pump as a continuous infusion at a rate of 0.1 mcg/kg/min. The duration of the drug infusion will be up to 48 hours.

Preoperative management will be conducted according to the patients' primary and concomitant diseases.

Placebo komparator: "Soluvit"

A placebo infusion after induction of anesthesia.

Patients in the placebo group will receive an equivalent amount of a colored solution of Soluvit.Soluvit (ATC B05XC; a yellow vitamin mixture indistinguishable from the investigational drug, levosimendan).

Preoperative management will be conducted according to the patients' primary and concomitant diseases.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean pulmonary artery pressure (mPAP)
Tidsramme: 24 hours at the end of surgery

Mean pulmonary artery pressure (mPAP) measured 24 hours after the end of surgery

24 hours at the end of surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pulmonary Vascular Resistance (PVR)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary vascular resistance

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Pulmonary Artery Pulsatility Index (PAPI)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary artery pulsatility index. PAPi = (PASP - PADP) / RAP (PASP - PADP): Pulmonary Artery Pulse Pressure. This is the difference between the pressure in the pulmonary artery when the heart contracts (systolic) and relaxes (diastolic).

RAP: Right Atrial Pressure.

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Pulmonary Artery Pressure (PAP)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary artery pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Arterial Blood Pressure (ABP)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Arterial blood pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Central Venous Pressure (CVP)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Central venous pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Cardiac Index (CI)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Cardiac index

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Systemic Vascular Resistance (SVR)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Systemic vascular resistance

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Right Ventricular Stroke Work Index (RVSWI)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Right ventricular stroke work index

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Pulmonary Capillary Wedge Pressure (PAWP)
Tidsramme: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary capillary wedge pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Ejection fraction
Tidsramme: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Ejection fraction (EF) of both the right and left ventricles (LVEF and RVEF)

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Right Ventricular End-Diastolic Volume (RVEDV)
Tidsramme: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Right ventricular end diastolic volume

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Right Ventricular systolic pressure (RVSP)
Tidsramme: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Right ventricular systolic pressure

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Fractional area change (FAC) of the right ventricle
Tidsramme: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Fractional area change (FAC) of the right ventricle

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Tricuspid annular plane systolic excursion (TAPSE)
Tidsramme: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Tricuspid annular plane systolic excursion

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Right ventricular free-wall longitudinal strain (RV FW LS)
Tidsramme: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Right ventricular free-wall longitudinal strain

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Quantitative troponin I level
Tidsramme: • before skin incision• 24 hours after the end of surgery• 48 hours after surgery

Quantitative concentration of troponin I

• before skin incision• 24 hours after the end of surgery• 48 hours after surgery
Vasoactive Inotropic Support
Tidsramme: • before skin incision • at the end of surgery • 4 hours after surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

In the perioperative period, the Vasoactive-Inotropic Score (VIS) will be calculated using the following formula:

VIS = dobutamine (mcg/kg/min) + dopamine (mcg/kg/min) + (100 × epinephrine (mcg/kg/min) + (100 × norepinephrine (mcg/kg/min)) + (10 × milrinone (mcg/kg/min))

• before skin incision • at the end of surgery • 4 hours after surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Residual Pulmonary Hypertension
Tidsramme: From the end of surgery up to 72 hours postoperatively

Number of participants with residual pulmonary hypertension, defined as postoperative mean pulmonary artery pressure (mPAP) > 25 mm Hg, measured by right heart catheterization in the postoperative period (up to 72 hours after surgery).

From the end of surgery up to 72 hours postoperatively
Incidence of reperfusion pulmonary edema
Tidsramme: From the end of surgery up to 72 hours postoperatively

Number of participants who develop pulmonary edema within 24 hours following pulmonary endarterectomy (PEA), confirmed by chest X-ray or chest CT and clinical criteria (including dyspnea, hypoxemia, and bilateral infiltrates), characterized by the presence of frothy secretions in the endotracheal tube (ETT), asymmetric opacities on chest X-ray, and an oxygenation index (PaO₂/FiO₂) < 300 mm Hg in the early postoperative period (up to 72 hours)

From the end of surgery up to 72 hours postoperatively
Incidence of cardiac arrhythmias
Tidsramme: 30 days

Proportion of participants who develop any new-onset cardiac arrhythmia (including atrial fibrillation/flutter, ventricular tachycardia) during the study period, as documented by 12-lead ECG or continuous cardiac monitoring.

30 days
Cardiovascular events: myocardial infarction or stroke
Tidsramme: 30 days

Number of participants with cardiovascular events, defined as myocardial infarction (MI) or stroke (cerebrovascular accident, CVA), occurring during the postoperative period.Myocardial infarction is defined according to the Fourth Universal Definition of Myocardial Infarction (elevated cardiac troponin with at least one of the following: ischemic symptoms, new ischemic ECG changes, or imaging evidence of new loss of viable myocardium). Stroke is defined as an acute episode of focal or global neurological dysfunction caused by infarction or hemorrhage in the brain, spinal cord, or retina, confirmed by neuroimaging (CT or MRI).

30 days
Respiratory Complications: Pneumothorax
Tidsramme: 30 days

Number of participants with postoperative pneumothorax, defined as the presence of air in the pleural cavity, confirmed by chest X-ray or chest CT, occurring during the postoperative period.

30 days
Neurological Complications: Seizures
Tidsramme: From enrollment to the end of treatment at 30 days

Number of participants with postoperative seizures, defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Diagnosis is based on clinical assessment and, when available, confirmed by electroencephalography (EEG).

From enrollment to the end of treatment at 30 days
Renal complications: acute kidney injury (AKI) according to KDIGO criteria
Tidsramme: 30 days

Number of participants with postoperative acute kidney injury (AKI), defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, occurring during the early postoperative period (up to 48 hours after surgery). AKI is defined as any of the following: increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours; or increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine output < 0.5 mL/kg/hour for 6 hours. AKI is staged as follows: Stage 1 (serum creatinine 1.5-1.9 times baseline or ≥ 0.3 mg/dL increase, or urine output < 0.5 mL/kg/hour for 6-12 hours), Stage 2 (serum creatinine 2.0-2.9 times baseline, or urine output < 0.5 mL/kg/hour for ≥ 12 hours), and Stage 3 (serum creatinine ≥ 3.0 times baseline, or increase to ≥ 4.0 mg/dL, or initiation of renal replacement therapy, or urine output < 0.3 mL/kg/hour for ≥ 24 hours, or anuria for ≥ 12 hours).

30 days
Renal replacement therapy (RRT)
Tidsramme: From enrollment to the end of treatment at 30 days

Number of participants who require renal replacement therapy (RRT) in the early postoperative period

From enrollment to the end of treatment at 30 days
Use of inhaled nitric oxide (NO) and/or iloprost
Tidsramme: 30 days

Number of participants requiring administration of inhaled nitric oxide (NO) and/or inhaled iloprost in the postoperative period. for the management of residual pulmonary hypertension or right ventricular dysfunction. This includes administration as monotherapy or in combination

30 days
Blood transfusion
Tidsramme: 30 days

Number of participants requiring perioperative blood transfusion, including packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelet concentrates, or cryoprecipitate, in the postoperative period. Transfusion requirements will be recorded as the number of participants receiving any transfusion.

30 days
Inotropic/vasopressor support
Tidsramme: From the end of surgery up to 72 hours postoperatively

Number of participants requiring postoperative inotropic and/or vasopressor support in the early postoperative period

From the end of surgery up to 72 hours postoperatively
Duration of mechanical ventilation (MV)
Tidsramme: 30 days

Total duration of invasive mechanical ventilation (MV) measured in hours (or days) from the time of intubation in the operating room or ICU until successful extubation. This includes the total time on the ventilator, both in the operating room and in the ICU, and includes any episodes of reintubation.

30 days
Duration of ICU stay
Tidsramme: 90 days

Total length of stay in the intensive care unit (ICU) measured in days from the time of admission to the ICU after surgery until discharge from the ICU to the general ward.

90 days
Duration of hospital stay
Tidsramme: 90 days

Total length of hospital stay measured in days

90 days
In-hospital mortality
Tidsramme: 90 days

yes/no

90 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. april 2025

Primær fullføring (Antatt)

1. november 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

28. april 2026

Først innsendt som oppfylte QC-kriteriene

28. oktober 2026

Først lagt ut (Faktiske)

4. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. oktober 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Data sharing is not planned as this is a single-center study and institutional regulations do not permit sharing of individual patient data.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere